Smoking Cessation Label Changes Could Lay Groundwork For Indications
This article was originally published in The Tan Sheet
Executive Summary
FDA drops its requirement for labeling provisions for NRTs on duration of use and concomitant use of tobacco or other NRTs. Meanwhile, the agency rejects citizen petition requests for additional NRT indications, but says it is open to working with sponsors on developing those indications.
You may also be interested in...
NRT Delivery Innovation Proposal In US Doesn't Deliver Expanded Indications
GSK's proposed usage for mouth spray product – reducing withdrawal symptoms, including nicotine craving – differs little from the first NRT product approved in US in 1984. Additional suggested label instructions primarily focus on stating NRTs can be used to reduce smoking or gradually stop tobacco use as opposed to quitting within a specified amount of time.
FDA Asks For Road Map To Broader NRT Indications
While the agency appears to favor moving to a broad harm reduction framework for indications for NRTs, including lifting limits on recommended duration of use, there remains “a lot of devil in the details” of expanding indications.
NRT Petition Calls On FDA To Greatly Expand Indications, Availability
FDA's stated commitment to a public health approach to drug regulation will be put to the test by a petition to expand nicotine replacement therapy indications and availability